Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
13 hedge funds and large institutions have $157K invested in Avenue Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
18% more funds holding
Funds holding: 11 → 13 (+2)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
81% less capital invested
Capital invested by funds: $849K → $157K (-$692K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.6K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$13.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.2K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$495 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$647K |
| 2 |
SAM
Shikiar Asset Management
New York
|
-$11.7K |
| 3 |
Bank of New York Mellon
New York
|
-$1.27K |
| 4 |
Morgan Stanley
New York
|
-$141 |
| 5 |
BlackRock
New York
|
-$71 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $37K | – | – | – |
|
|
2
Bank of New York Mellon
New York
| $36.5K | -$1.27K | -18 | -3% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $32.7K | +$43.6K | +617 | New |
|
4
State Street
Boston,
Massachusetts
| $21.5K | – | – | – |
|
|
TSS
5
Two Sigma Securities
New York
| $10.2K | +$13.6K | +193 | New |
|
|
SAM
6
Shikiar Asset Management
New York
| $9K | -$11.7K | -166 | -50% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $4.86K | +$1.2K | +17 | +23% |
|
8
Wells Fargo
San Francisco,
California
| $3.24K | – | – | – |
|
|
9
BlackRock
New York
| $1.32K | -$71 | -1 | -4% |
|
|
EL
10
EMFO LLC
Weston,
Florida
| $377 | – | – | – |
|
|
11
Osaic Holdings
Scottsdale,
Arizona
| $353 | +$495 | +7 | New |
|
|
12
Morgan Stanley
New York
| $195 | -$141 | -2 | -33% |
|
|
BC
13
Barrett & Company
Providence,
Rhode Island
| $11 | – | – | – |
|
|
SM
14
Sabby Management
Miami Beach,
Florida
| – | -$647K | -7,378 | Closed |
|
ATXI Hedge Fund Activity: Q3 2023 in Review
13 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q3 2023, worth a combined $157K — down 81% from $849K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ATXI positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $43.6K. The largest seller was Sabby Management, exiting entirely with an estimated $647K sold.
- 13 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q3 2023, up from 11 in Q2 2023.
- Funds reported $157K of Avenue Therapeutics, Inc. Common Stock stock for Q3 2023, down 81% quarter-over-quarter.
- 3 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q3 2023 and 1 closed out, a net change of +2 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q3 2023 was Vanguard Group, an estimated $43.6K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q3 2023 was Sabby Management, an estimated $647K sold.
Based on aggregated 13F filings for Q3 2023.